Patents by Inventor Yongke Zhang

Yongke Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190309080
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: February 27, 2019
    Publication date: October 10, 2019
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 10259878
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 16, 2019
    Assignee: APEXIGEN, INC.
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20180273630
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 27, 2018
    Inventors: Yongke ZHANG, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9994640
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 12, 2018
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9951136
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: April 24, 2018
    Assignee: APEXIGEN, INC.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • Publication number: 20170246297
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20170233483
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: December 19, 2016
    Publication date: August 17, 2017
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • Patent number: 9676861
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9556278
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 31, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9441042
    Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: September 13, 2016
    Assignee: Apexigen, Inc.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20160208007
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: January 14, 2016
    Publication date: July 21, 2016
    Inventors: Yongke ZHANG, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9266956
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 23, 2016
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20160032001
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: March 11, 2014
    Publication date: February 4, 2016
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20150307616
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: February 3, 2015
    Publication date: October 29, 2015
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • Patent number: 9085621
    Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: July 21, 2015
    Assignee: Apexigen, Inc.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang
  • Patent number: 9045543
    Abstract: The present invention discloses a humanized anti-CD20 antibody, which comprises a heavy chain comprising a polypeptide according to one of SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 36; and a light chain comprising apolypeptide according to one of SEQ ID NO: 34, SEQ ID NO: 35, or SEQ ID NO: 37. Comparing to murine-derived antibodies and human-mouse chimeric antibodies, said humanized anti-CD20 antibody maintains or improves high binding activity of the variable regions, meanwhile reduces the immunogenicity of chimeric antibodies, consequently achieves the effect of reducing medicine side effects and improving clinical treatment. The antibody disclosed by the present invention is efficiently expressed in animal cells, can be used for industrial production. It could be used in treating B cell lymphoma, leukaemia, or B cell-associated autoimmune disease with a wide application prospect.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: June 2, 2015
    Assignee: Bioex Therapeutics, Inc.
    Inventors: Jie Liu, Yongke Zhang
  • Patent number: 8986692
    Abstract: The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: March 24, 2015
    Assignees: Jiangsu Simcere Pharmaceutical R & D Co., Ltd., Apexigen Inc.
    Inventors: Pierre Li, Yaohuang Ke, Yongke Zhang, Weimin Zhu, Guoliang Yu, Fanxin Ma, Xin Fan
  • Patent number: 8957193
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: February 17, 2015
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20140377282
    Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
    Type: Application
    Filed: November 1, 2012
    Publication date: December 25, 2014
    Applicant: APEXIGEN, INC.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20140349395
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: June 5, 2014
    Publication date: November 27, 2014
    Applicant: Apexigen, Inc.
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU